§
PatentCue
Patent Intelligence
Join Waitlist Sign In
Patent US6689803B2 successfully refreshed from Google Patents.
← Back to Patent Explorer
US6689803B2 Expired / Lapsed US ⏱️ 0.0 years remaining

Compositions and methods for treating surgical adhesions

Assignee: IPXMEDICAL LLC
•
Filing: 2002-02-05
•
Granted: 2004-02-10
•
Expires: 2022-02-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

Inventors

  • 👤 William L. Hunter

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 15:43
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7042; A61K31/7052; A61K31/706; A61K31/7064; A61K31/045; A61K31/047; A61K31/075; A61K31/08; A61K31/13; A61K31/135; A61K31/138; A61K31/16; A61K31/17; A61K31/21; A61K31/215; A61K31/22; A61K31/223; A61K31/28; A61K31/33; A61K31/335; A61K31/337; A61K31/35; A61K31/352; A61K31/357; A61K31/36; A61K31/365; A61K31/366; A61K31/395; A61K31/40; A61K31/4015; A61K31/4025; A61K31/41; A61K31/425; A61K31/426; A61K31/427; A61K31/435; A61K31/4353; A61K31/437; A61K31/44; A61K31/4427; A61K31/443; A61K31/47; A61K31/4738; A61K31/4745; A61K31/475; A61K31/495; A61K31/505; A61K31/519; A61K33/00; A61K33/06; A61K33/16; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/12; A61K47/14; A61K47/30; A61K47/34; A61K9/00; A61K9/0012; A61K9/0014; A61K9/0019; A61K9/0048; A61K9/10; A61K9/107; A61K9/1075; A61K9/12; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647; A61K9/48; A61K9/50; A61K9/51; A61K9/5107; A61K9/513; A61K9/5146; A61K9/5153; A61K9/70; A61K9/7007; B; B82; B82Y; B82Y5/00

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 33 words
A method for treating or preventing surgical adhesions, comprising administering to a patient in need thereof a therapeutically effective amount of an anti-microtubule compound-containing, pharmaceutically acceptable composition, wherein said anti-microtubule compound is paclitaxel.
Claim 2
Independent Claim 33 words
A method for treating or preventing surgical adhesions, comprising administering to a patient in need thereof a therapeutically effective amount of an anti-microtubule compound-containing, pharmaceutically acceptable composition, wherein said anti-microtubule compound is paclitaxel.
Claim 3
Dependent Claim 18 words
The method according to claim 1 wherein said paclitaxel-containing composition comprises paclitaxel and a polymer or a copolymer.
Claim 4
Dependent Claim 18 words
The method according to claim 2 wherein said composition contains a copolymer of lactic acid and glycolic acid.
Claim 5
Dependent Claim 11 words
The method according to claim 2 wherein said polymer is poly(caprolactone).
Claim 6
Dependent Claim 12 words
The method according to claim 2 wherein said polymer is poly(lactic acid).
Claim 7
Dependent Claim 17 words
The method according to claim 2 wherein said composition contains a copolymer of poly(lactic acid) and poly(caprolactone).
Claim 8
Dependent Claim 11 words
The method according to claim 2 wherein said polymer is polyethyleneglycol.
Claim 9
Dependent Claim 13 words
The method according to claim 2 wherein said copolymer is ethylene vinyl acetate.
Claim 10
Dependent Claim 15 words
The method according to claim 1 wherein said paclitaxel-containing composition comprises paclitaxel and isopropyl myristate.
Claim 11
Dependent Claim 15 words
The method according to claim 1 wherein said paclitaxel-containing composition comprises paclitaxel and a glycol.
Claim 12
Dependent Claim 11 words
The method according to claim 10 wherein said glycol is ethoxydiglycol.
Claim 13
Dependent Claim 15 words
The method according to claim 2 wherein said copolymer is a diblock or triblock copolymer.
Claim 14
Dependent Claim 16 words
The method according to claim 2 wherein said composition contains 0.5% to 20% paclitaxel by weight.
Claim 15
Dependent Claim 19 words
The method according to claim 2 wherein said composition is delivered as a paste, a film, or a wrap.
Claim 16
Dependent Claim 14 words
The method according to claim 2 wherein said composition is delivered as a spray.
Claim 17
Dependent Claim 18 words
The method according to claim 2 wherein said composition is applied to the surface of a surgical implant.

References Cited (Backward Citations)

US4391797A Cited
EP0038567A1 Cited
JPS6163613A Cited
EP0262681A1 Cited
EP0274846A1 Cited
US5092885A Cited
EP0288794A2 Cited
US4863968A Cited
US4904697A Cited
US4753965A Cited
EP0294905A1 Cited
US5667764A Cited
WO1990001969A1 Cited
US5614587A Cited
US5936035A Cited
US5411947A Cited
US5484809A Cited
WO1991007154A1 Cited
WO1991010424A1 Cited
WO1991011193A1 Cited
EP0470246A1 Cited
WO1991012779A1 Cited
WO1992000747A1 Cited
EP0470569A1 Cited
WO1992005200A1 Cited
US5330756A Cited
US5466455A Cited
US5476954A Cited
WO1992012717A2 Cited
WO1992015286A1 Cited
US5620971A Cited
US6074659A Cited
WO1993006792A1 Cited
EP0543653A1 Cited
WO1993011120A1 Cited
EP0551182A1 Cited
US5958741A Cited
EP0568310A1 Cited
EP0567816A1 Cited
WO1994001425A1 Cited
US5665761A Cited
US5641803A Cited
US5621001A Cited
US5496846A Cited
US5882881A Cited
WO1994007880A1 Cited
EP0669916A1 Cited
WO1994012484A1 Cited
US5606083A Cited
US5565439A Cited
US5972992A Cited
US5356927A Cited
US5631278A Cited
WO1994012158A1 Cited
US5580998A Cited
US5576450A Cited
US5550261A Cited
US5587493A Cited
US5571917A Cited
US5599942A Cited
US5580997A Cited
US5532388A Cited
US5443458A Cited
US5981568A Cited
US5811447A Cited
US5770609A Cited
US5733925A Cited
US6096331A Cited
US5654449A Cited
US5576345A Cited
US5541232A Cited
EP0706376A1 Cited
US5886026A Cited
US5994341A Cited
US5716981A Cited
US5616608A Cited
US5789189A Cited
US5567417A Cited
US5573781A Cited
US5565478A Cited
US5696153A Cited
US5626862A Cited
US5651986A Cited
US5587459A Cited
US5583153A Cited
EP0717041A1 Cited
US5654337A Cited
US5612052A Cited
US6551610B2 Cited
US5714159A Cited
US5627206A Cited
EP0747385A1 Cited
EP0747066A2 Cited
US5873904A Cited
US5977163A Cited
US6132765A Cited
US5635531A Cited
US6465427B1 Cited
US5773464A Cited
US6413539B1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2007-02-09 2007-08-11 2008-02-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2011-02-09 2011-08-11 2012-02-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2015-02-09 2015-08-11 2016-02-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag